Phase II study of imatinib (Glivec) administered as a daily oral treatment in patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 10 Dec 2005 New trial record.